| scholarly article | Q13442814 |
| P50 | author | Claudia Martini | Q43257386 |
| Gino Giannaccini | Q46649946 | ||
| Antonio Lucacchini | Q56916066 | ||
| Antonio Ciapparelli | Q59040450 | ||
| Liliana Dell'Osso | Q72932960 | ||
| P2093 | author name string | Lionella Palego | |
| Giovanni Battista Cassano | |||
| Luciano Biondi | |||
| Nannina Sarno | |||
| Simona Elmi | |||
| P2860 | cites work | Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics | Q28371424 |
| Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine | Q34048732 | ||
| Clozapine-induced agranulocytosis. Incidence and risk factors in the United States | Q34062064 | ||
| Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms | Q34345969 | ||
| Clozapine: new research on efficacy and mechanism of action | Q38362817 | ||
| Clozapine--pharmacokinetic investigations and biochemical effects in man. | Q38716946 | ||
| Cigarette smoking and clinically significant drug interactions | Q40952943 | ||
| The expanding indications for clozapine | Q41565505 | ||
| Evaluation of treatment-resistant schizophrenia | Q41640700 | ||
| Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? | Q41685984 | ||
| Simultaneous analysis of clozapine, clomipramine and their metabolites by reversed-phase liquid chromatography. | Q43616083 | ||
| Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection | Q43794493 | ||
| Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women. | Q50989475 | ||
| Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. | Q51031082 | ||
| Influence of patient-related variables on clozapine plasma levels. | Q52055220 | ||
| Clozapine as a treatment tool: only in resistant schizophrenic patients? | Q53974695 | ||
| A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. | Q54362647 | ||
| N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. | Q55065832 | ||
| Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors | Q57131608 | ||
| Clozapine for Treatment-Refractory Schizophrenia, Schizoaffective Disorder, and Psychotic Bipolar Disorder | Q60633571 | ||
| Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection | Q67982487 | ||
| Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age | Q69795312 | ||
| Clozapine for treatment-refractory mania | Q71085936 | ||
| Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients | Q73296823 | ||
| Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study | Q74212194 | ||
| P433 | issue | 3 | |
| P921 | main subject | psychosis | Q170082 |
| patient | Q181600 | ||
| P304 | page(s) | 473-480 | |
| P577 | publication date | 2002-04-01 | |
| P1433 | published in | Progress in Neuro-Psychopharmacology & Biological Psychiatry | Q15616665 |
| P1476 | title | Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables | |
| P478 | volume | 26 |
| Q91918214 | A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology |
| Q37983363 | A review of the use of clozapine levels to guide treatment and determine cause of death |
| Q43296441 | ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients |
| Q89145780 | Clinical Pharmacokinetics of Atypical Antipsychotics: An Update |
| Q36804367 | Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response |
| Q38260932 | Clozapine serum concentrations in dopamimetic psychosis in Parkinson's disease and related disorders |
| Q37078947 | Clozapine-related EEG changes and seizures: dose and plasma-level relationships |
| Q36024542 | Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia |
| Q46913948 | Genetic association analysis of N-methyl-D-aspartate receptor subunit gene GRIN2B and clinical response to clozapine |
| Q35111188 | Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine |
| Q93055463 | Population Pharmacokinetics of Clozapine: A Systematic Review |
| Q33571417 | Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia |
| Q83277424 | Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2 |
| Q64068344 | Relationship between Clozapine-Induced Electroencephalogram Abnormalities and Serum Concentration of Clozapine in Japanese Patients with Treatment-Resistant Schizophrenia |
| Q39739062 | Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice |
| Q37598900 | Sex-specific differences in side effects of psychotropic drugs: genes or gender? |
Search more.